NONSMALL CELL LUNG CANCER
Clinical trials for NONSMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new NONSMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for NONSMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Electric fields zap lung cancer in major trial
Disease control CompletedThis study tested whether adding a portable, battery-operated device to standard treatments helps people with advanced lung cancer live longer. The device, worn on the chest, delivers low-intensity electric fields (called TTFields) aimed at slowing or stopping cancer cell growth.…
Matched conditions: NONSMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: NovoCure GmbH • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New immune drug trial challenges standard chemo for lung cancer
Disease control CompletedThis large, completed Phase 3 trial tested whether a new immunotherapy drug (cemiplimab) works better than standard platinum-based chemotherapy as the first treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have high levels of a ma…
Matched conditions: NONSMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Scientists test genetic blueprint to Fine-Tune cancer radiation
Disease control CompletedThis small, early-stage study explored whether doctors could use a patient's unique tumor genetics to personalize their radiation dose. It involved people with stage 2 or 3 non-small cell lung cancer that couldn't be removed by surgery. The main goal was to see if this tailored a…
Matched conditions: NONSMALL CELL LUNG CANCER
Phase: EARLY_PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
New immune therapy drug enters human testing for tough cancers
Disease control CompletedThis first-in-human study tested a new experimental drug called HMBD-002, which targets a protein on cancer cells called VISTA. The trial aimed to find a safe dose and schedule for giving HMBD-002 alone and combined with the approved immunotherapy drug pembrolizumab (Keytruda®) i…
Matched conditions: NONSMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Hummingbird Bioscience • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC